You are here

Article info

Article menu

Download PDFPDF

Commentary
Targeting of netrin-1 by monoclonal antibody NP137 inhibits the EMT in cancer

Authors

  • Xueli Xia Department of Laboratory Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, ChinaDepartment of Immunology, Jiangsu University School of Medicine, Zhenjiang, Jiangsu, China PubMed articlesGoogle scholar articles
  • Kai Yin Department of General Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China PubMed articlesGoogle scholar articles
  • Shengjun Wang Department of Laboratory Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, ChinaDepartment of Immunology, Jiangsu University School of Medicine, Zhenjiang, Jiangsu, China PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Shengjun Wang; sjwjs{at}ujs.edu.cn; Dr Kai Yin; jsyinkai{at}163.com
View Full Text

Citation

Xia X, Yin K, Wang S
Targeting of netrin-1 by monoclonal antibody NP137 inhibits the EMT in cancer
Journal for ImmunoTherapy of Cancer 2024;12:e008937. doi: 10.1136/jitc-2024-008937

Publication history

  • Accepted March 18, 2024
  • First published April 4, 2024.
Online issue publication 
April 04, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.